The spleen tyrosine kinase (SYK) is especially important for the neutrophil Fc receptor and β2 integrin signaling and thus selective SYK inhibitors have been developed and are under investigation for hematological malignancies (See trial details in Table 2). Here, SYK is linked to hematologic disorder.